<![CDATA[PI3K/AKT Pathway Biology, Capivasertib, and Biomarker Testing]]>

capivasertibfulvestrantNeutral

AI Analysis

Summary

Dr. Erica L. Mayer reviews the scientific rationale for capivasertib combined with fulvestrant in HR+/HER2- advanced breast cancer, highlighting PI3K/AKT pathway alterations present in approximately half of patients and guideline recommendations for this combination in endocrine-resistant disease.

Importance:3/10

Sentiment:

0.00

PI3K/AKT pathwaybreast cancerbiomarker testingcapivasertibfulvestranthormone receptor positiveHER2-negativeadvanced breast cancer

Read the original article

Published by Cancer Network on August 28, 2026 12:03 PM

Read Original